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Abstract
Objective: Characterize the flux of platelet-endothelial cell adhesion molecule (PECAM-1) antibody-coated super-
paramagnetic iron oxide nanoparticles (IONPs) across the blood-brain barrier (BBB) and its biodistribution in vitro and in
vivo.
Methods: Anti-PECAM-1 IONPs and IgG IONPs were prepared and characterized in house. The binding affinity of these
nanoparticles was investigated using human cortical microvascular endothelial cells (hCMEC/D3). Flux assays were
performed using a hCMEC/D3 BBB model. To test their immunospecificity index and biodistribution, nanoparticles were
given to Sprague Dawley rats by intra-carotid infusion. The capillary depletion method was used to elucidate their
distribution between the BBB and brain parenchyma.
Results: Anti-PECAM-1 IONPs were ,130 nm. The extent of nanoparticle antibody surface coverage was 63.668.4%. Only
6.3961.22% of labeled antibody dissociated from IONPs in heparin-treated whole blood over 4 h. The binding affinity of
PECAM-1 antibody (KD) was 32 nM with a maximal binding (Bmax) of 17610
5 antibody molecules/cell. Anti-PECAM-1 IONP
flux across a hCMEC/D3 monolayer was significantly higher than IgG IONP’s with 31% of anti-PECAM-1 IONPs in the
receiving chamber after 6 h. Anti-PECAM-1 IONPs showed higher concentrations in lung and brain, but not liver or spleen,
than IgG IONPs after infusion. The capillary depletion method showed that 17612% of the anti-PECAM-1 IONPs crossed the
BBB into the brain ten minutes after infusion.
Conclusions: PECAM-1 antibody coating significantly increased IONP flux across the hCMEC/D3 monolayer. In vivo results
showed that the PECAM-1 antibody enhanced BBB association and brain parenchymal accumulation of IONPs compared to
IgG. This research demonstrates the benefit of anti-PECAM-1 IONPs for association and flux across the BBB into the brain in
relation to its biodistribution in peripheral organs. The results provide insight into potential application and toxicity
concerns of anti-PECAM-1 IONPs in the central nervous system.
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Introduction
Multifunctional superparamagnetic iron oxide nanoparticles
(IONPs) have various applications, such as diagnosis and therapy
of the central nervous system (CNS) [1,2]. For example, IONPs
have drawn increasing attention as T2 magnetic resonance
imaging (MRI) contrast agents in preclinical and clinical studies
to evaluate blood-brain barrier (BBB) dysfunction related to
tumors and other pathologies such as stroke and carotid
atherosclerosis [3,4]. Multifunctional IONPs also provide the
possibility to deliver therapeutic agents to the brain and
concurrently monitor their tissue distribution using MRI [5,6].
One of the challenges for CNS applications of IONPs is the ability
to cross the highly restricted BBB. Previous research has suggested
evidence of IONP flux across the BBB by analyzing the whole
brain concentration. However, there have been no reports
distinguishing between IONPs in the brain vessels and BBB cells
[7]; or they only showed the therapeutic efficacy of co-delivered
compounds in animal models of brain tumors [8]. To advance the
potential applications of multifunctional IONPs in the CNS, there
is an urgent need to understand how they associate with, and
transcytose across, the BBB in vitro and in vivo.
Brain capillary endothelial cells cooperate with pericytes,
astrocytes, and neurons to generate and maintain the unique
barrier properties of the BBB. The BBB plays a crucial role in
safeguarding the brain from endogenous and exogenous com-
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pounds, which includes most therapeutics [9]. A recent study
evaluated the uptake and flux of IONPs using human brain-
derived endothelial cells. Flux of IONPs that lacked targeting
moieties on the surface was very limited under normal conditions
[10]. A promising strategy to enhance IONP flux across the BBB is
to use a BBB targeting moiety. Platelet-endothelial cell adhesion
molecule (PECAM-1) (CD31) is a member of the immunoglobulin
superfamily that is constitutively expressed on endothelial cell
membranes and is involved in transcytosis of activated leukocytes
across the BBB in neuroinflammation [11,12,13]. Furthermore,
significant upregulation of PECAM-1 in neuroinflammation
provides a potential to target the CNS for the treatment of
neurological conditions such as stroke and brain tumor [13]. Pure
PECAM-1 antibody has been shown to target the endothelial
lumen, but does not internalize into endothelial cells [14].
However, anti-PECAM-1 coated nanocarriers can enter the
endothelial cells through a unique vesicular internalization
pathway, cell adhesion molecule (CAM)-mediated endocytosis
[15]. Anti-PECAM-1 antibodies conjugated to diverse therapeutic
cargoes and nanocarriers provided robust intracellular drug
delivery into endothelial cells [16]. However, how anti-PECAM-
1 nanocarriers associate with and traffic across the BBB, one of the
most important endothelial cell barriers, still needs to be defined.
We hypothesized that PECAM-1 antibody will increase IONP
BBB association, trafficking across the BBB, and change its
distribution profile in vitro and in vivo. In this study, we
characterized anti-PECAM-1 IONPs for size, stability in blood,
and association to immortalized human cortical microvascular
endothelial (hCMEC/D3) cells. We investigated the association,
and flux across the BBB over 6 h, of anti-PECAM-1 IONPs using
hCMEC/D3 cells. Furthermore, anti-PECAM-1 IONP brain
accumulation and biodistribution in peripheral organs were
studied in Sprague Dawley rats. The capillary depletion method
was used to test anti-PECAM-1 IONP in vivo distribution between
the BBB endothelial cells and brain parenchyma. The results of
this study demonstrate the potential of anti-PECAM-1 IONPs to
target and transcytose across the BBB and enter into the brain
parenchyma, providing valuable insight into the feasibility of anti-
PECAM-1 IONP as a brain targeting MRI contrast agent and/or
drug delivery system for the CNS.
Materials and Methods
Ethics Statement
This study used 21 male Sprague-Dawley rats, weighing
300625 g (mean 6 SD), that were housed individually prior to
study in the University of Kentucky Division of Laboratory
Animal Resources Facility under a 12:12 h light:dark cycle at
7068uF and 30 to 70% humidity. The rats had free access to 2018
Harlan diet and reverse osmosis water. Animal work was approved
by the University of Kentucky Institutional Animal Care and Use
Committee (Protocol 2008-0272). The research was conducted in
accordance with the Guiding Principles in the Use of Animals in
Toxicology.
Reagents
Mouse anti-human anti-PECAM-1 was created and purified in
house through the use of a hybridoma cell line (P2B1) purchased
from the Developmental Studies Hybridoma Bank (Iowa City, IA).
For in vivo studies, a mouse anti-rat anti-PECAM-1 (Clone TLD-
3A12) was purchased from Millipore (Billerica, MA). Nonspecific
mouse IgG was from Jackson Immuno (West Grove, PA). Na125I
was purchased from Perkin Elmer (Boston, MA). All other
reagents were from Sigma-Aldrich (St. Louis, MO).
Iron oxide nanoparticle synthesis
IONPs were synthesized using a previously reported method
[17]. Briefly, ferric chloride hexahydrate (Fe3+) and ferrous
chloride tetrahydrate (Fe2+) were dissolved in deionized water
(Fe3+:Fe2+ = 2:1), followed by adding ammonium hydroxide
dropwise under an N2 atmosphere at 85uC. After 1 h, the solution
was placed on a magnet to collect black brown particles, which
were washed repeatedly using pure ethanol [18,19]. IONPs were
dried overnight in a vacuum drying oven. Properties, such as size
and zeta potential of the IONPs, were determined in our
laboratories. All of the methods have been previously reported
[20].
Protein iodination for antibody tracing
IgG and the anti-PECAM-1 antibody were labeled with Na125I
using the Iodogen method. In brief, 100 mg of antibody was mixed
with 15 mCi of Na125I for 5 minutes in glass tubes coated with
Iodogen reagent. Following the reaction, the now-labeled protein
was purified using Bio-Rad Labs packed spin columns (Hercules,
CA). The extent of iodination was determined by protein
precipitation followed by analysis of radioactivity in the pellet
and supernatant [21].
Preparation and characterization of antibody-modified
iron oxide surfaces
Iron oxide nanoparticles were suspended in PBS and sonicated
with a probe sonicator at a power output of 10 W for 1 minute,
then transferred to a sonication bath for 30 minutes prior to
surface coating. To couple anti-PECAM-1 or IgG antibody to iron
oxide nanoparticles, a physioabsorption technique was employed.
Either anti-PECAM-1 or IgG antibodies were incubated with the
nanoparticles at a solution concentration equivalent to 10,000
antibodies/mm2 particle surface area, 1.2 times the theoretical
monolayer coating based on antibody size and particle surface
area. Radiolabeled anti-PECAM-1 or IgG in PBS was added to
the suspended nanoparticles and incubated for 1 h at 25uC.
Particles were washed with PBS 3 times and centrifuged for 30
minutes at 22,000 g and then suspended in 1% BSA-PBS. The
antibody was traced in both supernatant and pellets using a
PerkinElmer 2470 Automatic Gamma Counter to determine the
extent of surface coverage.
Antibody-modified iron oxide nanoparticle stability in
whole blood
To determine coating stability in vivo, particles were incubated in
heparin-treated whole rat blood at 37uC for 24 h at equivalent
concentrations utilized in vivo (0.015 mg nanoparticles/ml whole
blood). At pre-determined time points, aliquots of whole blood
were centrifuged for 30 minutes at 22,000 g and separated from
the nanoparticles and analyzed on the gamma counter.
Cell lines and culture conditions
hCMEC/D3 cells were obtained under license from INSERM,
France. The cells were maintained in endothelial growth medium-
2 supplemented with 2.5% fetal bovine serum, 1% penicillin and
streptomycin, 0.1% fibroblast growth factor, 0.01% hydrocorti-
sone and 0.025% vascular endothelial growth factor, insulin-like
growth factor and endothelial growth factor, under 37uC and 5%
CO2. Cells were passaged into collagenated culture flasks every 3–
4 days when they reached approximately 85%–95% confluence
[22,23,24].
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PECAM-1 antibody binding affinity to hCMEC/D3 cells
hCMEC/D3 cells were seeded on 36 well plates at a density of
50,000 cells/cm2. They were incubated with serial dilutions from
0.78 to 100 nM of 125I anti-PECAM-1 or 125I IgG antibodies for
2 h (n = 3). The supernatants in the donor chamber were collected
and the cells were washed 3 times with PBS at 4uC. The hCMEC/
D3 monolayer was lysed with 1% Triton X-100 in 1.0 N NaOH.
The cell lysate and supernatant (including the washing solution)
radioactivities were measured using a Wallac 1470 WizardTM
gamma counter. Bmax and KD were calculated using GraphPad
Prism (GraphPad Software, San Diego, CA, USA).
Anti-PECAM-1 IONP cell association and flux using the
human brain endothelial cell line hCMEC/D3 in vitro BBB
model
hCMEC/D3 cells were seeded on type I collagen pre-coated 6
well Transwell filters (polycarbonate 12 mm, pore size 3.0 mm) at
a density of 50,000 cells/cm2. Flux assays were performed 7-10
days after seeding [22,23]. The tightness of the hCMEC/D3
monolayer was measured as transepithelial electrical resistance
(TEER) using a RMA321-Millicell-ERS voltohmmeter (Millipore
Corp, Billerica, MA). To monitor flux through the paracellular
pathway, lucifer yellow (LY, 100 mM) was added to the medium
on the donor side of the cells. Samples of the medium from the
donor chamber were collected at time zero and from the receiving
chamber hourly for 6 h for LY concentration analysis. LY
fluorescence was determined in a SpectraMax M5 Multi-Mode
Microplate Reader (Molecular Devices, Sunnyvale, CA) at
lex\lem = 450/530 nm and compared with a standard of LY in
endothelial growth medium-2.
Anti-PECAM-1 and IgG IONPs were introduced into the
donor chamber at 0.05 mg/mL, as used in our previous
cytotoxicity study on IONPs [20]. Samples (100 mL) were collected
from the donor chamber at time 0 and the receiving chamber
hourly for 6 h for iron concentration analysis by inductively
coupled plasma mass spectrometry (ICP-MS) (Agilent 7500cx,
Santa Clara, CA, USA). The donor chamber was removed and
the cells washed 3 times using PBS at 4uC. The hCMEC/D3
monolayer was lysed with 1% Triton X-100 in 1.0 N NaOH. Iron
concentration in the cell lysate and supernatant (including washing
solution) was measured using ICP-MS. Flux rates of LY and
nanoparticles were calculated by linear regression for the first 6 h.
Two-way ANOVA followed by Bonferroni multiple comparisons
was used to test for significant flux differences among the
treatment groups and times using GraphPad Prism (GraphPad
Software, San Diego, CA). Statistical significance was accepted at
p,0.05.
Brain targeting and biodistribution by anti-PECAM-1
IONPs
Antibody-coated iron oxide nanoparticles were prepared
similarly as before with one exception. Both anti-PECAM-1-
and IgG-coated particles were incubated with 5% 125I labeled IgG
at a concentration of 10 mg/ml. This was done to prevent any
detached labeled antibody from accumulating in the vasculature,
thus providing a false positive for adhesion. Carotid artery
injection was employed to delivery 10 mg/kg 125I anti-PECAM-
1 IONPs (n = 3) and 125I IgG IONPs (n = 3). Briefly, the rat was
anesthetized under ketamine/xylazine anesthesia (75 and 5 mg/
kg), and its left carotid artery exposed. Following ligation of the
external carotid, occipital and common carotid arteries, PE60
tubing containing heparin (100 U/ml, in 0.9% NaCl) was inserted
into the common carotid. The 10 mg/ml 125I anti-PECAM-1
IONPs and 125I IgG IONPs were infused in 1 mlover 1 min at a
dose of 10 mg/kg. All the rats were sacrificed 10 min after
infusion. The brain was harvested and cleaned of meninges and
surface vessels. Blood and organs such as the liver, spleen and lung
were collected for biodistribution analysis using the gamma
counter. The results were compared between 125I anti-PECAM-
1 and 125I IgG IONPs using t-test or one-way ANOVA. The
localization ratio (LR) was calculated as the percent of the injected
dose per gram of tissue divided by percent of the injected dose per
gram of blood. The specificity index was calculated as the LR of
the targeted formulation (anti-PECAM-1 IONPs) divided by the
non-targeted counterpart (IgG IONPs). The specificity index
indicates specific targeting to organs, normalized by organ weights
and the fraction contained in blood [25]. One-way ANOVA
followed by Tukey’s test was used to test for significant differences
of IgG IONP and anti-PECAM-1 IONP biodistribution among
different organs. All results are reported as mean 6 SD. Statistical
significance was accepted at p,0.05.
BBB integrity assessment
Five minutes before termination, the rat was given 6 mg Na
fluorescein (334 Da) interartery in 1 ml saline over 40 s as a BBB
permeability marker. Postmortem brain cortex was obtained to
quantify fluorescein content. Fluorescence was determined in a
SpectraMax M5 Multi-Mode Microplate Reader (Molecular
Devices, Sunnyvale, CA) at lex\lem = 493/514 nm. The results
among control, IgG IONP, and anti-PECAM-1 IONP groups
were compared using one-way ANOVA (GraphPad Prism).
Anti-PECAM-1 IONP distribution between the BBB
endothelial cells and brain parenchyma using the
capillary depletion method
The capillary depletion method was used to separate brain
parenchyma from capillary tissue [26,27]. After a 10 mg/kg 125I
anti-PECAM-1 IONP or 125I IgG IONP injection into the left
carotid artery, a 20 s washout was conducted using PBS at a flow
rate of 20 ml/min immediately before decapitation [28]. The
forebrain from the left hemisphere was isolated from 125I anti-
PECAM-1 IONP and 125I IgG IONP treated rats (n = 3) and the
lateral ventricle choroid plexus in the perfused hemisphere
removed. The tissue was homogenized in 3.5 ml of buffer
containing 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM
NaH2PO4, 1 mM MgSO4, 10 mM glucose and 10 mM HEPES
at pH 7.4. Dextran (70,000 g/mol) was then added to 18% (w/v)
and the sample further briefly homogenized. After centrifugation
at 54006g for 15 min at 4uC, the supernatant (brain rich fraction)
and pellet (capillary rich fraction) were carefully separated for
measurement of 125I by gamma counter. The percentage of the
forebrain 125I in the capillary rich fraction was calculated as
follows: (Mass of 125I in capillary rich fraction/Mass of 125I in
capillary rich fraction and capillary depleted fraction)*100
The apparent permeability coefficient
The apparent permeability coefficients (Papp, cm/s) of LY, IgG
IONPs and anti-PECAM-1 IONPs were calculated using
GraphPad Prism. The first 6 h flux data were used with R2 cutoff
.0.8. The Papp was calculated using the equation: Papp = (DQ/
Dt)/(area*CD) [29]. DQ/Dt is the linear appearance rate obtained
from the profile of the transported amount of the substrate against
time (mg/s). CD is the initial donor concentration of LY or
nanoparticles (mg/cm3). Area is the surface area of the cell
monolayer (4.67 cm2 for a 6-well plate).
Anti-PECAM-1 SPIONs Target the Brain
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Results
Anti-PECAM-1/IgG coating efficiency
After removal of unbound antibody, the surface coverage was
determined to be 63.668.4% (Figure 1A). Based on the primary
nanoparticle size of 80 nm (Figure 1B), this corresponds to 19.1 mg
antibody/mg of nanoparticle or 105 antibody molecules/nano-
particle. DLS measurements showed the size increased from
80 nm to 130 nm after addition of anti-PECAM-1 (Figure 1B),
indicating uniform coating with slight aggregation, as the antibody
size is ,15 nm in length. The zeta potential of the nanoparticles
decreased from 210 to 28 mV (Figure 1C).
Stability of antibody-coated iron oxide nanoparticles in
whole blood
Because anti-PECAM-1 IONPs and IgG IONPs were prepared
by surface antibody adsorption, their stability in blood is very
important for in vivo study. The 125I labeled IgG antibody
exhibited minimal detachment from nanoparticles for up to 4 h
at 37uC. At 4 h, only 6.461.2% of labeled antibody was detected
in the heparin-treated blood after centrifugation. Between 4 and
24 h this increased to 46.269.5%, likely due to the antibody on
the nanoparticle surface being replaced with higher affinity serum
proteins (Figure 2). The insignificant coating loss over 4 h suggests
these nanoparticle modifications will stay stable throughout the
circulation life and time frame of in vivo experiments.
PECAM-1 binding affinity to the human endothelial cell
hCMEC/D3
hCMEC/D3 is a human BBB cell line developed in 2005.
Previous research showed that it expressed PECAM-1 [24].
However, the binding affinity between hCMEC/D3 and PECAM-
1 antibody was not known. Figure 3 shows that anti-PECAM-1,
but not non-specific control IgG, adhered specifically to this BBB
cell model. The predicted antibody saturation (Bmax) was
determined to be 16.946105 molecules/cell, with a binding
constant (KD) of 32 nM, which is relatively low compared with
a designed PECAM-1 antibody (a paired monoclonal antibody) for
vascular targeting, with reported affinities between 0.5–5 nM [30].
However, previous research showed that relatively low affinity
antibodies boost brain uptake by transcytosis targeting [31]. In the
next experiment, anti-PECAM-1 IONP flux across the human
endothelial cell hCMEC/D3 was tested.
Anti-PECAM-1 IONP flux and cell association using a
hCMEC/D3 in vitro BBB model
The TEER of the hCMEC/D3 in vitro BBB model (Figure 4)
was tested every other day after the cells were seeded. After 7-10
days, the resistances were .90 V/cm2, similar to previously
reported [22]. The permeability coefficient of LY, the indication of
paracellular flux, was 2.960.261026 cm/s.
Anti-PECAM-1 IONP flux was significantly higher than IgG
IONPs and LY from 3 h to 6 h. The permeability coefficient after
6 h of anti-PECAM-1 IONPs was 6.760.261026 cm/s, versus
4.860.261026 cm/s for IgG IONPs, and 2.960.261026 cm/s
for LY (Figure 5A). After 6 h, 30% of anti-PECAM-1 IONPs was
in the receiving chamber and ,45% of anti-PECAM-1 IONPs
Figure 1. Surface modification of IONPs by anti-PECAM-1
antibody. Iron oxide nanoparticles were incubated with excess 125I
labeled antibody and purified by centrifugation. The bound antibody
was tested after each centrifugation (A). Size of IONPs before and after
anti-PECAM-1 antibody surface modification (B). Zeta potential of IONPs
before and after anti-PECAM-1 antibody surface modification (C). (N = 3,
mean 6 SD)
doi:10.1371/journal.pone.0081051.g001
Figure 2. Antibody coating stability in whole blood. 125I labeled
nanoparticles show minimal detachment of coating for up to 4 h,
suggesting coating stability and targeting capability in vivo. (N = 3,
mean 6 SD)
doi:10.1371/journal.pone.0081051.g002
Figure 3. PECAM-1 antibody binding affinity to hCMEC/D3
cells. IgG exhibited undetectable levels of binding, whereas anti-
PECAM-1 affinity was 32 nM, with a Bmax of 17610
5 molecules/cell.
(N = 3, mean 6 SD)
doi:10.1371/journal.pone.0081051.g003
Anti-PECAM-1 SPIONs Target the Brain
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was associated with the hCMEC/D3 cells, significantly higher
than IgG IONPs (Figure 5B). PECAM-1 antibody significantly
enhanced the flux of IONPs across the hCMEC/D3 monolayer in
vitro. In the next experiment, anti-PECAM-1 IONP brain
targeting, accumulation, and biodistribution were studied using
Sprague Dawley rats.
Anti-PECAM-1 IONP association and biodistribution in
brain and peripheral organs
Using 125I tracing, we tested anti-PECAM-1 IONP targeting
ability to brain and peripheral organs. As shown in figure 6A,
the % dose per mL of blood in anti-PECAM-1 IONP treated rats
was significantly lower than IgG IONP treatment, suggesting
increased removal from blood and enhanced tissue accumulation.
Ten min after infusion, 0.1160.01% of the anti-PECAM-1 IONPs
dose was associated with each gram of brain, which was
significantly higher than anti-IgG IONPs (Figure 6B). The
specificity index (the ratio between targeted and non targeted
control) was calculated to test the anti-PECAM-1 IONP’s brain
targeting ability. Anti-PECAM-1 IONPs specificity in the brain
was 5-fold higher than with IgG IONPs (Figure 6C). PECAM-1
targeting did not change anti-PECAM-1 IONP distribution in
liver and spleen compared with IgG. However, anti-PECAM-1
IONP accumulation was significantly increased in the lungs
(Figure 7).
Figure 4. Schema of the TranswellH system used for flux studies.
doi:10.1371/journal.pone.0081051.g004
Figure 5. Anti-PECAM-1 IONP flux across hCMEC/D3 cells and
cell association results. Anti-PECAM-1 IONP (0.05 mg/ml), IgG IONP
(0.05 mg/ml) and LY (100 mM) flux across hCMEC/D3 cells for 6 h (A).
Anti-PECAM-1 IONP and IgG IONP distribution in the donor and
receiving chambers and hCMEC/D3 cells at 6 h (B). (N = 3, mean 6 SD)
* Significantly different compared to IgG IONPs.
doi:10.1371/journal.pone.0081051.g005
Figure 6. Percent of the anti-PECAM-1- and IgG IONPs dose in
blood and brain association. The blood (A) and brain (B) levels of
125I labeled anti-PECAM-1-IONPs after intra-arterial infusion in rats,
expressed as the percentage of injected dose (% Injected Dose (ID),
10 mg/kg). Specific tissue accumulation of anti-PECAM-1 IONPs
compared with IgG IONPs in brain, calculated as the specificity index
(SI). SI values above 1 represent specific targeting in an organ over IgG
IONPs (C). * Significantly different compared to IgG IONPs. (N = 3, mean
6 SD)
doi:10.1371/journal.pone.0081051.g006
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Effect of Anti-PECAM-1 IONPs on blood-brain barrier
integrity
Since anti-PECAM-1 IONP brain association was significantly
increased, it was important to determine whether that changed the
BBB permeability. Ten min after anti-PECAM-1 IONP injection
the concentration of the BBB permeability marker, fluorescein in
the brain, did not change significantly compared with the control
and IgG IONP groups (Figure 8).
Anti-PECAM-1 IONP distribution between brain capillary
cells and brain parenchyma
For brain delivery systems, determination of whether or not
they can enter the brain parenchyma is crucial. Our permeability
results showed that anti-PECAM-1 IONPs did not alter BBB
permeability. Understanding the anti-PECAM-1 IONP distribu-
tion between the brain capillary cells and parenchyma would
provide evidence for transcellular flux. The capillary depletion
results showed that 10 min after infusion, 82612% of anti-
PECAM-1 IONPs were associated with the capillary fraction and
17612% of them entered the brain (Figure 9). The capillary
depletion assay was also carried out with brain from IgG-IONPs
treated rats. However, because of the low brain association of IgG
IONPs, all radioactivity level readings were indistinguishable from
background radioactivity.
Discussion
The use of vasculature-targeting antibodies, especially against
PECAM-1, has been utilized before for lung targeting, injury
treatment, [32] and as tumor contrast agents [33]. Anti-PECAM-1
nanocarriers can internalize into the cell through cellular adhesion
molecule (CAM)-mediated endocytosis [15], which provides the
potential to target the BBB and increase nanocarrier flux across
the BBB. Previous research showed that IONPs coupled with
affinity moieties targeted to receptors, such as transferrin, can
facilitate IONP flux across the BBB [34]. However, little is known
whether anti-PECAM-1 surface-modified IONPs enhance brain
flux across the BBB and change the distribution of IONPs between
the BBB and brain parenchyma. In this study, we explored anti-
PECAM-1 IONP targeting, transcytosis across the BBB, and
biodistribution in the brain and peripheral organs.
We demonstrated that iron oxide nanoparticles can be
sufficiently coupled with both IgG and anti-PECAM-1 using a
non covalant physioabsorption strategy. It was determined that
over 60% of the nanoparticle surface was coated with antibody
(105 antibody molecules per nanoparticle). Previous research has
demonstrated that clustering of the CAM through antibody
binding can result in efficient internalization of anti-PECAM-1
nanoparticles, depending upon epitope of binding [15]. Using a
non-covalant targeting strategy, it was expected that upon contact
with serum proteins they would inactivate the targeting coating,
lowering the treatment efficacy. Contrary to this, it was seen that
the coating on these nanoparticles stays intact for up to 4 h, vastly
longer than the circulation half life of up to 2 h for uncoated
particles [35]. The IgG IONPs and anti-PECAM-1 we developed
have desirable properties to investigate BBB targeting and flux in
vitro and in vivo.
In our in vitro flux study, LY showed higher flux at 1 h compared
with anti-PECAM-1 IONPs and IgG IONPs. At 2 h, the fluxes of
LY, anti-PECAM-1 IONPs and IgG IONPs were similar. After
2 h, anti-PECAM-1 IONP flux was significantly higher than LY
and IgG IONPs. These results provided evidence that the
paracellular pathway was not the major pathway for anti-
PECAM-1 IONPs flux. Anti-PECAM-1 IONPs use a different
mechanism of flux across the BBB compared with IgG IONPs.
There are multiple pathways for internalization involving vesicles
,300 nm in diameter. Clathrin- and caveolea-mediated endocy-
tosis are the two major pathways for nanoparticle internalization
[36,37,38,39]. IgG IONPs are likely to be taken up through these
pathways. Limited transcytosis was observed in our study, which
was consistent with a previous study in which the flux of three
different surface-charged IONPs was studied across a human BBB
model in vitro. Very limited flux was observed over 25 h [10]. On
the other hand, clustered PECAM-1 can be internalized by a novel
endocytic pathway, CAM endocytosis [15], which was distinct
from clathrin and caveolin-mediated endocyosis [40,41]. Our in
vitro flux study showed that PECAM-1 antibody surface modifi-
cation significantly improved BBB targeting and flux across the
BBB. Previous research showed that intercellular adhesion
Figure 7. Biodistribution of IgG IONPs and anti-PECAM-1
IONPs in rats. The liver, spleen and lung levels of 125I labeled anti-
PECAM-1 IONPs measured 10 min after intra-arterial infusion in rats,
expressed as the percentage of injected dose (%ID, 10 mg/kg).
* Significantly different compared to IgG IONPs. (N = 3, mean 6 SD)
doi:10.1371/journal.pone.0081051.g007
Figure 8. BBB permeability measured by fluorescein concen-
tration 10 min after completion of intra-arterial infusion in
rats. Rats received saline, 10 mg/kg IgG IONPs, or 10 mg/kg anti-
PECAM-1 IONPs and were terminated 10 min after infusion. (N = 3,
mean 6 SD)
doi:10.1371/journal.pone.0081051.g008
Figure 9. Capillary depletion results. The level of anti-PECAM-1
IONPs and IgG IONPs concentrations in the capillary-rich fraction and
brain-rich fraction. (N = 3, mean 6 SD). BDL: Below detectable limits.
doi:10.1371/journal.pone.0081051.g009
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molecule 1(ICAM-1)-targeted nanocarriers, which also use the
CAM-endocytosis pathway, provide considerable promise to
enhance delivery of larger multivalent carriers to the CNS [25].
Another study also showed that anti-PECAM-1 nanocarriers
demostrated significantly higher brain association [42]. However,
they analyzed whole brain tissue including the BBB, brain
parenchyma and the blood in the brain vessels. The present study
provides a better understanding of the assocation and flux of anti-
PECAM-1 nanoparticles across the BBB in vitro and in vivo.
In our in vivo study, anti-PECAM-1 IONPs did not change BBB
permeability, further suggesting that anti-PECAM-1 IONPs
crossed the BBB through a transcellular pathway rather than a
paracellular pathway. We are not aware of any reports on how
anti-PECAM-1 IONPs influence BBB permeability. However,
previous research showed that anti-PECAM nanocarriers did not
change endothelial monolayer integrity compared with a IgG
nanocarrier [42]. The lack of anti-PECAM IONP increased BBB
permeability decreases its potential adverse effects related to the
BBB.
The level of anti-PECAM-1 IONP in the blood was significantly
lower than IgG IONP, suggesting enhanced tissue accumulation.
The results were consistent with anti-PECAM-1 IONP brain
association results. Compared with IgG IONP, anti-PECAM-1
IONP significantly increased IONP brain association 10 min after
infusion. There was 0.1160.01% of the dose associated with a
gram of brain tissue 10 min after infusion. For comparison, the
brain uptake of morphine, a neuroactive lipid soluble small
molecule, is 0.008160.001% of the dose/g rat brain [43]. The
uptake of anti-PECAM-1 IONPs was higher than morphine, a
regularly administered neuroactive small molecule with the
capability of crossing the BBB. This demonstrates the potential
application of PECAM-1 antibody for brain delivery. The
transferrin receptor is the most studied targeting receptor for
brain uptake [44]. Most previous studies of transferrin-surface-
modified nanoparticles focused on the improvement of diagnosis
and therapeutic effects rather than brain uptake [34,45]. The
brain delivery of the transferrin ligand was less than 0.3% of the
dose using a healthy animal model [46]. A recent study compared
ICAM-1 antibody and transferrin-surface-modified nanocarriers
for brain targeting. It was found that they are both effective, but
transferrin showed more advantages on smaller conjugates and
ICAM-1 worked better for larger multivalent carriers [24]. In our
study anti-PECAM-1 IONPs showed a similar specificity index as
previously reported anti-ICAM-1 nanocarriers [25]. We expected
PECAM-1 antibody would show similar brain targeting as ICAM-
1, however, more research needs to be done to compare PECAM-
1, ICAM-1 and transferrin for brain targeting. Furthermore, the
actual extent of transferrin transcytosis is still unknown. Some
studies showed that only a miniscule amount of transferrin was
trancytosed across the brain capillary cells and accumulated in the
brain [47,48]. Our in vitro results provide evidence that anti-
PECAM-1 IONPs can transcytose across a human BBB mono-
layer in vitro model.
We investigated the distribution between the BBB and brain
parenchyma using the capillary depletion method to better
characterize anti-PECAM-1 IONP transcytosis in vivo. Our results
showed that 10 min after intra-arterial infusioin, 17612% of anti-
PECAM-1 IONPs crossed the BBB and associated with brain
parenchyma. However, the majority of anti-PECAM-1 IONPs
was still associated with the BBB cells. CAM-mediated endocytosis
is a relatively slow process. One study investigated anti-PECAM
nanocarrier internalization into human endothelial cells over time.
After 15 minutes, 20% of anti-PECAM nanocarrier was internal-
ized. However, there is little known about anti-PECAM-1
transcytosis [42]. Our in vitro flux study showed that 4.5% of
anti-PECAM-1 IONPs flux cross the BBB monolayer over 1 h.
Our studies demonstrated the potential of anti-PECAM-1 IONPs
to cross the BBB in vitro and in vivo. However, a longer time point
study is required to better understand how effectively anti-
PECAM-1 enhances flux across the BBB.
The biodistribution results of anti-PECAM-1 IONPs demo-
strated that PECAM-1 antibody did not increase anti-PECAM-1
IONP accumulation in the liver or spleen 10 min after injection.
More study at longer time points is needed to fully understand the
disposition of anti-PECAM-1 IONPs in the liver and spleen.
However, PECAM-1 antibody significantly increased the IONP
accumulation in the lung. This result was consistent with previous
reports that an anti-PECAM-1 nanocarrier is a good candidate for
pulmonary targeting [49,50]. This is due to the massive surface
area provided by lung capillary beds. For brain targeted delivery,
high accumulation in the lung has potential to cause side effects
there. However, we can take advantage of this property for certain
diseases. For example, about 15–20% of patients with non-small
cell lung cancer (NSCLC) develop brain metastasis [51]. Anti-
PECAM-1 nanocarriers can target lung and brain simultaneously
and be taken up through the CAM-mediated endocytosis pathway
[42]. Furthermore, recent clinical research showed that PECAM-1
could be a potential prognostic factor and a novel therapeutic
target for the effective treatment of NSCLC [52]. Therefore, anti-
PECAM-1 IONPs have potential to be used to target lung and
NSCLC, while treating potential brain metastasis. More research
needs to be conducted to test anti-PECAM-1 IONPs in a brain
metastasis model and investigate how they associate with the blood
tumor barrier and tumor cells.
Conclusions
This work demostrated that anti-PECAM-1-modified IONPs
enhance flux across the BBB in vitro and in vivo, which holds
promise to deliver IONPs or other therapeutic agents to the CNS
without compromising BBB permeability. This effect was a result
of both the capacity of anti-PECAM-1 IONPs to target the BBB
and the ability to transcytose across it into the brain. Meanwhile,
anti-PECAM-1 IONPs demonstrated increased lung accumula-
tion, which provides the potential to simultaneously target lung
and lung cancer derived-brain metastasis. Future studies investi-
gating anti-PECAM-1 IONPs using a lung cancer brain metastasis
model in vivo should provide evidence about how anti-PECAM-1
IONPs associate with the blood tumor barrier and metastatic
brain tumor. Anti-PECAM-1 IONPs have great potential to be
employed in the diagnosis and therapy of CNS diseases such as
NSCLC-originating brain metastasis.
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